Antihypertensive Response to Losartan and Genetic Polymorphisms

NACompletedINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Hypertension
Interventions
DRUG

losartan potassium

Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).

DRUG

Comparator: Hydrochlorothiazide

Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00617877 - Antihypertensive Response to Losartan and Genetic Polymorphisms | Biotech Hunter | Biotech Hunter